Inside E2’s Hēlo System: A New Approach to Pulmonary Embolism Thrombectomy

Advancements in pulmonary embolism thrombectomy have improved patient outcomes, but the core tradeoff has remained the same: go big for peripheral clot capture and accept more procedural burden, or stay smaller and sacrifice efficiency.

In this episode of MedTech Unboxed, Steve talks with Dan Rose, CEO of E2 – Endovascular Engineering, about the unmet need in pulmonary embolism treatment and how E2’s Hēlo Thrombectomy System is designed to rethink that tradeoff.

Their conversation unpacks the technology behind the Hēlo platform, including its combination of a 24-French clot engagement zone with a 15-French heart-crossing catheter, plus aspiration and mechanical agitation to engage, break down, and remove clot while returning blood in real time.

Dan also shares what the team has seen in early clinical data, including strong clot-burden reduction and very low blood loss, and what that could mean for the future of pulmonary embolism thrombectomy.

What you’ll hear in this episode:

• Why pulmonary embolism remains a major unmet need
• Where anticoagulation and thrombolytics still fall short for intermediate- and high-risk PE patients
• The big-bore vs. small-bore tradeoff in current thrombectomy systems, and why that matters in a stressed right heart
• How E2’s Hēlo system uses a self-expanding funnel, mechanical agitation, and aspiration to go in small and act big
• Why integrated blood return matters for patient stability, procedural confidence, and overall efficiency
• Dan’s perspective on what the early clinical and investor response suggests about the future of PE thrombectomy